Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Receivables: 2022-2024

Historic Receivables for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $92,000.

  • Orchestra BioMed Holdings' Receivables fell 54.78% to $52,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $316,000, marking a year-over-year decrease of 12.47%. This contributed to the annual value of $92,000 for FY2024, which is 7.07% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Receivables stood at $92,000 for FY2024, which was down 7.07% from $99,000 recorded in FY2023.
  • Orchestra BioMed Holdings' 5-year Receivables high stood at $99,000 for FY2023, and its period low was $92,000 during FY2024.
  • Its 3-year average for Receivables is $95,667, with a median of $96,000 in 2022.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Receivables climbed by 3.12% in 2023, and later decreased by 7.07% in 2024.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' Receivables stood at $96,000 in 2022, then increased by 3.12% to $99,000 in 2023, then fell by 7.07% to $92,000 in 2024.